HIA
ADMS

Harbor Investment Advisory’s Adamas Pharmaceuticals ADMS Stock Holding History

Harbor Investment Advisory’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-719
Closed -$2K – 1243
2020
Q1 		$2K Buy
+719
New +$3.22K ﹤0.01% 955

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Harbor Investment Advisory's ADMS Position: Q2 2020 in Review

Harbor Investment Advisory sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 719 shares — an estimated $2K sold.

Harbor Investment Advisory first reported a position in ADMS in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • Harbor Investment Advisory reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Harbor Investment Advisory sold 719 Adamas Pharmaceuticals shares in Q2 2020, an estimated $2K.
  • Harbor Investment Advisory first reported a position in Adamas Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Harbor Investment Advisory's Adamas Pharmaceuticals position peaked at $2K in Q1 2020.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Harbor Investment Advisory's 13F filing for Q2 2020, filed 16 Jul 2020.